Use of G-CSF-stimulated marrow in allogeneic hematopoietic stem cell transplantation settings: A comprehensive review

Clinical Transplantation

Volumn 25, Issue 1, 2011, Pages 13-23

  Chang, Ying Jun ^a   Huang, Xiao Jun ^b  

^a HEBEI MEDICAL UNIVERSITY   (China)

^b PEKING UNIVERSITY PEOPLE S HOSPITAL   (China)

Author keywords

Allogeneic hematopoietic stem cell transplantation; Bone marrow; Granulocyte colony stimulating factor

Indexed keywords

BUSULFAN; CD16 ANTIGEN; CD19 ANTIGEN; CD3 ANTIGEN; CD34 ANTIGEN; CD56 ANTIGEN; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; CYTARABINE; ETOPOSIDE; GRANULOCYTE COLONY STIMULATING FACTOR; MELPHALAN; METHOTREXATE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; THYMOCYTE ANTIBODY;

ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LYMPHOCYTIC LEUKEMIA; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ALLOGENIC BONE MARROW TRANSPLANTATION; BONE MARROW; CANCER RELAPSE; CANCER SURVIVAL; CD4+ CD25+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CHRONIC MYELOID LEUKEMIA; GRAFT REJECTION; GRAFT VERSUS HOST REACTION; HLA MATCHING; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; IN VITRO STUDY; IN VIVO STUDY; MYELODYSPLASTIC SYNDROME; NEUTROPHIL COUNT; PRIORITY JOURNAL; REVIEW; WHOLE BODY RADIATION;

BONE MARROW; GRAFT REJECTION; GRANULOCYTE COLONY-STIMULATING FACTOR; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HEMATOPOIETIC STEM CELLS; HUMANS; TRANSPLANTATION, HOMOLOGOUS; TREATMENT OUTCOME;

EID: 79551707003     PISSN: 09020063     EISSN: 13990012     Source Type: Journal    
DOI: 10.1111/j.1399-0012.2010.01298.x     Document Type: Review

References (62)

1. Korbling M, Anderlini P. Peripheral blood stem cell versus bone marrow allotransplantation: does the source of hematopoietic stem cells matter? Blood 2001: 98: 2900.
2. Gallardo D, De La Camara R, Nieto JB et al. Is mobilized peripheral blood comparable with bone marrow as a source of hematopoietic stem cells for allogeneic transplantation from HLA-identical sibling donors? A case-control study. Haematologica 2009: 94: 1282.
3. Cutler C, Li S, Ho VT et al. Extended follow-up of methotrexate-free immunosuppression using sirolimus and tacrolimus in related and unrelated donor peripheral blood stem cell transplantation. Blood 2007: 109: 3108.
4. Stem Cell Trialists' Collaborative Group Allogeneic peripheral blood stem-cell compared with bone marrow transplantation in the management of hematologic malignancies: an individual patient data meta-analysis of nine randomized trials. J Clin Oncol 2005: 23: 5074.
5. Baker KS, Fraser CJ. Quality of life and recovery after graft-versus-host disease. Best Pract Res Clin Haematol 2008: 21: 333.
6. Chiang KY, Haight A, Horan J et al. Clinical outcomes and graft characteristics in pediatric matched sibling donor transplants using granulocyte colony-stimulating factor-primed bone marrow and steady-state bone marrow. Pediatr Transplant 2007: 11: 279.
7. Donato M, Champlin R. Granulocyte colony-stimulating factor - primed allogeneic bone marrow transplants: capturing the advantages of blood stem cell transplants without increased risk of chronic graft-versus-host disease. Biol Blood Marrow Transplant 2000: 6: 419.
8. Elfenbein GJ, Sackstein R, Oblon DJ. Do G-CSF mobilized, peripheral blood-derived stem cells from healthy, HLA-identical donors really engraft more rapidly than do G-CSF primed, bone marrow-derived stem cells? No! Blood Cells Mol Dis 2004: 32: 106.
9. Frangoul H, Nemecek ER, Billheimer D et al. A prospective study of G-CSF primed bone marrow as a stem-cell source for allogeneic bone marrow transplantation in children: a Pediatric Blood and Marrow Transplant Consortium (PBMTC) study. Blood 2007: 110: 4584.
10. Isola L, Scigliano E, Fruchtman S. Long-term follow-up after allogeneic granulocyte colony-stimulating factor - primed bone marrow transplantation. Biol Blood Marrow Transplant 2000: 6: 428.
11. Isola LM, Scigliano E, Skerrett D et al. A pilot study of allogeneic bone marrow transplantation using related donors stimulated with G-CSF. Bone Marrow Transplant 1997: 20: 1033.
12. Ji SQ, Chen HR, Wang HX et al. G-CSF-primed haploidentical marrow transplantation without ex vivo T cell depletion: an excellent alternative for high-risk leukemia. Bone Marrow Transplant 2002: 30: 861.
13. Ji SQ, Chen HR, Yan HM et al. Anti-CD25 monoclonal antibody (basiliximab) for prevention of graft-versus-host disease after haploidentical bone marrow transplantation for hematological malignancies. Bone Marrow Transplant 2005: 36: 349.
14. Ostronoff F, Ostronoff M, Souto-Maior AP et al. Prospective trial of mycophenolate mofetil-cyclosporine A prophylaxis for acute GVHD after G-CSF stimulated allogeneic bone marrow transplantation with HLA-identical sibling donors in patients with severe aplastic anemia and hematological malignancies. Clin Transplant 2009: 23: 33.
15. Ostronoff M, Ostronoff F, Souto Maior P et al. Pilot study of allogeneic G-CSF-stimulated bone marrow transplantation: harvest, engraftment, and graft-versus-host disease. Biol Blood Marrow Transplant 2006: 12: 729.
16. Serody JS, Sparks SD, Lin Y et al. Comparison of granulocyte colony-stimulating factor (G-CSF)-mobilized peripheral blood progenitor cells and G-CSF-stimulated bone marrow as a source of stem cells in HLA-matched sibling transplantation. Biol Blood Marrow Transplant 2000: 6: 434.
17. Wang HX, Yan HM, Duan LN et al. Haploidentical hematopoietic stem cell transplantation in child hematologic malignancies with G-CSF-mobilized marrow grafts without T-cell depletion: a single-center report of 45 cases. Pediatr Hematol Oncol 2009: 26: 119.
18. Kim HJ, Min WS, Cho BS et al. Overcoming various comorbidities by G-CSF-primed unmanipulated BM SCT in adult patients with AML. Bone Marrow Transplant 2009: 44: 345.
19. Lowenthal RM, Ragg SJ, Anderson J, Nicholson L, Harrup RA, Tuck D. A randomized controlled clinical trial to determine the optimum duration of G-CSF priming prior to BM stem cell harvesting. Cytotherapy 2007: 9: 158.
20. Morton J, Hutchins C, Durrant S. Granulocyte-colony-stimulating factor (G-CSF)-primed allogeneic bone marrow: significantly less graft-versus-host disease and comparable engraftment to G-CSF-mobilized peripheral blood stem cells. Blood 2001: 98: 3186.
21. Styczynski J, Debski R, Krenska A, Wysocki M. [G-CSF-primed bone marrow as a stem-cell source for allogeneic bone marrow transplantation in children]. Med Wieku Rozwoj 2008;12(4 Pt 2): 1112.
22. Elfenbein GJ, Sackstein R. Primed marrow for autologous and allogeneic transplantation: a review comparing primed marrow to mobilized blood and steady-state marrow. Exp Hematol 2004: 32: 327.
23. Elfenbein GJ. Granulocyte-colony stimulating factor primed bone marrow and granulocyte-colony stimulating factor mobilized peripheral blood stem cells are equivalent for engraftment: which to choose? Pediatr Transplant 2005: 9(Suppl 7): 37.
24. Wang HX, Yan HM, Liu J et al. Haploidentical hematopoietic stem-cell transplantation for non-Hodgkin lymphoma with bone marrow involvement. Leuk Lymphoma 2009: 50: 1488.
25. Grupp SA, Frangoul H, Wall D, Pulsipher MA, Levine JE, Schultz KR. Use of G-CSF in matched sibling donor pediatric allogeneic transplantation: a consensus statement from the Children's Oncology Group (COG) Transplant Discipline Committee and Pediatric Blood and Marrow Transplant Consortium (PBMTC) Executive Committee. Pediatr Blood Cancer 2006: 46: 414.
26. Chandy M, George B, Mathews V et al. A fludarabine based conditioning regimen associated with a good survival following HLA identical sibling/family donor transplants in patients with aplastic anemia. Blood 2009, 114: Abstract 1194.
27. Santarone S, De Angelis G, Di Bartolomeo E et al. Non T-depleted bone marrow transplantation from haploidentical related donor in hematological malignancies. Blood 2009, 114: Abstract 2291.
28. Couban S, Messner HA, Andreou P et al. Bone marrow mobilized with granulocyte colony-stimulating factor in related allogeneic transplant recipients: a study of 29 patients. Biol Blood Marrow Transplant 2000: 6: 422.
29. Mavroudis DA, Read EJ, Molldrem J et al. T cell-depleted granulocyte colony-stimulating factor (G-CSF) modified allogenic bone marrow transplantation for hematological malignancy improves graft CD34+ cell content but is associated with delayed pancytopenia. Bone Marrow Transplant 1998: 21: 431.
30. Ji SQ, Chen HR, Wang HX, Yan HM, Pan SP, Xun CQ. Comparison of outcome of allogeneic bone marrow transplantation with and without granulocyte colony-stimulating factor (lenograstim) donor-marrow priming in patients with chronic myelogenous leukemia. Biol Blood Marrow Transplant 2002: 8: 261.
31. Shier LR, Schultz KR, Imren S et al. Differential effects of granulocyte colony-stimulating factor on marrow- and blood-derived hematopoietic and immune cell populations in healthy human donors. Biol Blood Marrow Transplant 2004: 10: 624.
32. Chiang KY, Lamb L, Clark J, Worthington-White D, Rich I, Henslee-Downey PJ. Assessment of G-CSF stimulated BM hematopoietic stem cells in normal donors. Cytotherapy 2002: 4: 55.
33. Chang YJ, Zhao XY, Huo MR, Huang XJ. Expression profiles of adhesion molecules on naive T cells in bone marrow grafts of healthy donors treated with granulocyte colony-stimulating factor. Transpl Immunol 2009: 21: 228.
34. Jun HX, Jun CY, Yu ZX. A direct comparison of immunological characteristics of granulocyte colony-stimulating factor (G-CSF)-primed bone marrow grafts and G-CSF-mobilized peripheral blood grafts. Haematologica 2005: 90: 715.
35. Jun HX, Jun CY, Yu ZX. In vivo induction of T-cell hyporesponsiveness and alteration of immunological cells of bone marrow grafts using granulocyte colony-stimulating factor. Haematologica 2004: 89: 1517.
36. Pan L, Delmonte J Jr, Jalonen CK, Ferrara JL. Pretreatment of donor mice with granulocyte colony-stimulating factor polarizes donor T lymphocytes toward type-2 cytokine production and reduces severity of experimental graft-versus-host disease. Blood 1995: 86: 4422.
37. Anderlini P, Champlin RE. Biologic and molecular effects of granulocyte colony-stimulating factor in healthy individuals: recent findings and current challenges. Blood 2008: 111: 1767.
38. Sun LX, Ren HY, Shi YJ, Wang LH, Qiu ZX. Recombinant human granulocyte colony-stimulating factor significantly decreases the expression of CXCR3 and CCR6 on T cells and preferentially induces T helper cells to a T helper 17 phenotype in peripheral blood harvests. Biol Blood Marrow Transplant 2009: 15: 835.
39. Toh HC, Sun L, Soe Y et al. G-CSF induces a potentially tolerant gene and immunophenotype profile in T cells in vivo. Clin Immunol 2009: 132: 83.
40. Anderlini P. Effects and safety of granulocyte colony-stimulating factor in healthy volunteers. Curr Opin Hematol 2009: 16: 35.
41. Joo YD, Lee SM, Lee SW et al. Granulocyte colony-stimulating factor-induced immature myeloid cells inhibit acute graft-versus-host disease lethality through an indoleamine dioxygenase-independent mechanism. Immunology 2009: 128(1 Suppl): e632.
42. Franzke A, Piao W, Lauber J et al. G-CSF as immune regulator in T cells expressing the G-CSF receptor: implications for transplantation and autoimmune diseases. Blood 2003: 102: 734.
43. Tayebi H, Kuttler F, Saas P et al. Effect of granulocyte colony-stimulating factor mobilization on phenotypical and functional properties of immune cells. Exp Hematol 2001: 29: 458.
44. Ji SQ, Chen HR, Xun CQ, Wang HX, Pan SP, Xiao MH. The effect of G-CSF-stimulated donor marrow on engraftment and incidence of graft-versus-host disease in allogeneic bone marrow transplantation. Clin Transplant 2001: 15: 317.
45. Koyama M, Hashimoto D, Aoyama K et al. Plasmacytoid dendritic cells prime alloreactive T cells to mediate graft-versus-host disease as antigen-presenting cells. Blood 2009: 113: 2088.
46. Bittencourt H, Rocha V, Chevret S et al. Association of CD34 cell dose with hematopoietic recovery, infections, and other outcomes after HLA-identical sibling bone marrow transplantation. Blood 2002: 99: 2726.
47. Pulsipher MA, Chitphakdithai P, Logan BR et al. Donor, recipient, and transplant characteristics as risk factors after unrelated donor PBSC transplantation: beneficial effects of higher CD34+ cell dose. Blood 2009: 114: 2606.
48. Chang YJ, Zhao XY, Huo MR, Luo XH, Huang XJ. [CD34 cells and T cell subsets in recombinant human granulocyte colony-stimulating factor primed bone marrow grafts from donors with different characteristics]. Zhonghua Xue Ye Xue Za Zhi 2008: 29: 512.
49. Berger M, Figari O, Bruno B et al. Lymphocyte subsets recovery following allogeneic bone marrow transplantation (BMT): CD4+ cell count and transplant-related mortality. Bone Marrow Transplant 2008: 41: 55.
50. Xiao-Jun H, Lan-Ping X, Kai-Yan L et al. Partially matched related donor transplantation can achieve outcomes comparable with unrelated donor transplantation for patients with hematologic malignancies. Clin Cancer Res 2009: 15: 4777.
51. Lu DP, Dong L, Wu T et al. Conditioning including antithymocyte globulin followed by unmanipulated HLA-mismatched/haploidentical blood and marrow transplantation can achieve comparable outcomes with HLA-identical sibling transplantation. Blood 2006: 107: 3065.
52. Chen XH, Zhang C, Zhang X et al. Role of antithymocyte globulin and granulocyte-colony stimulating factor-mobilized bone marrow in allogeneic transplantation for patients with hematologic malignancies. Biol Blood Marrow Transplant 2009: 15: 266.
53. Huang XJ, Chang YJ, Zhao XY. Maintaining hyporesponsiveness and polarization potential of T cells after in vitro mixture of G-CSF mobilized peripheral blood grafts and G-CSF primed bone marrow grafts in different proportions. Transpl Immunol 2007: 17: 193.
54. Feng X, Kajigaya S, Solomou EE et al. Rabbit ATG but not horse ATG promotes expansion of functional CD4+CD25highFOXP3+ regulatory T cells in vitro. Blood 2008: 111: 3675.
55. Mohty M. Mechanisms of action of antithymocyte globulin: T-cell depletion and beyond. Leukemia 2007: 21: 1387.
56. Sinitsyn Y, Malone A, Mandeli J et al. Combined bone marrow and peripheral blood progenitor cell autografts for patients with poor mobilization. Cytotherapy 2009: 11: 457.
57. Xu LP, Liu KY, Liu DH et al. The inferiority of G-PB to rhG-CSF-mobilized blood and marrow grafts as a stem cell source in patients with high-risk acute leukemia who underwent unmanipulated HLA-mismatched/haploidentical transplantation: a comparative analysis. Bone Marrow Transplant 2009; doi.
58. Luo XH, Chang YJ, Xu LP, Liu DH, Liu KY, Huang XJ. The impact of graft composition on clinical outcomes in unmanipulated HLA-mismatched/haploidentical hematopoietic SCT. Bone Marrow Transplant 2009: 43: 29.
59. Xu LP, Luo XH, Chang YJ et al. High CD4/CD8 ratio in allografts predicts adverse outcomes in unmanipulated HLA-mismatched/haploidentical hematopoietic stem cell transplantation for chronic myeloid leukemia. Ann Hematol 2009: 88: 1015.
60. Ooi J. Cord blood transplantation in adults. Bone Marrow Transplant 2009: 44: 661.
61. Kurtzberg J, Prasad VK, Carter SL et al. Results of the Cord Blood Transplantation Study (COBLT): clinical outcomes of unrelated donor umbilical cord blood transplantation in pediatric patients with hematologic malignancies. Blood 2008: 112: 4318.
62. Hwang WY, Samuel M, Tan D, Koh LP, Lim W, Linn YC. A meta-analysis of unrelated donor umbilical cord blood transplantation versus unrelated donor bone marrow transplantation in adult and pediatric patients. Biol Blood Marrow Transplant 2007: 13: 444.